Goldman Sachs’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Goldman Sachs’s Portfolio ELOX Stock Details ELOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-690	Closed	-$45K	–	6831
2021 Q3	$45K	Buy	+690	New	+$42.5K	﹤0.01%	6070
2019 Q4	–	Sell	-490	Closed	-$89K	–	5472
2019 Q3	$89K	Buy	490 +93	+23%	+$26.5K	﹤0.01%	4982
2019 Q2	$158K	Sell	397 -106	-21%	-$44.6K	﹤0.01%	4851
2019 Q1	$235K	Buy	503 +106	+27%	+$51.5K	﹤0.01%	4736
2018 Q4	$191K	Sell	397 -505	-56%	-$279K	﹤0.01%	4841
2018 Q3	$615K	Sell	902 -804	-47%	-$515K	﹤0.01%	4309
2018 Q2	$1.17M	Buy	+1,706	New	+$1.11M	﹤0.01%	3975

Other funds holding ELOX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Goldman Sachs's ELOX Position: Q4 2021 in Review

Goldman Sachs sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2021, closing a stake of 690 shares — an estimated $45K sold.

Goldman Sachs first reported a position in ELOX in Q2 2018 and held it in 7 quarters. The position peaked at $1.17M in Q2 2018. 38 funds tracked by Wall St. Rank hold ELOX as of Q4 2021.

Goldman Sachs reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 690 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $45K.
Goldman Sachs first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Goldman Sachs's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $1.17M in Q2 2018.
38 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.